31.01

3.16% 0.95

After Hours: 32.00 0.99 +3.19%

Newamsterdam Pharma Company Nv (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

Newamsterdam Pharma Company Nv stock is traded at $31.01, with a volume of 740.82K. It is up +3.16% in the last 24 hours and down -11.43% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Previous Close:

$30.06

Open:

$30.97

24h Volume:

740.82K

Relative Volume:

0.96

Market Cap:

$3.57B

Revenue:

$22.50M

Net Income/Loss:

$-203.82M

P/E Ratio:

-17.75

EPS:

-1.7469

Net Cash Flow:

$-148.03M

1W Performance:

+5.33%

1M Performance:

-11.43%

6M Performance:

+17.95%

1Y Performance:

+32.46%

1-Day Range:

$30.52

$32.04

1-Week Range:

$28.81

$32.04

52-Week Range:

$14.06

$42.00

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name

Newamsterdam Pharma Company Nv

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

35 206 2971

Address

GOOIMEER 2-35, NARRDEN

Employee

100

Twitter

Next Earnings Date

Latest SEC Filings

NAMS's Discussions on Twitter

Compare NAMS vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NAMS Newamsterdam Pharma Company Nv	31.01	3.46B	22.50M	-203.82M	-148.03M	-1.7469
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Buy
Oct-20-25	Resumed	H.C. Wainwright	Buy
Aug-25-25	Initiated	Wells Fargo	Overweight
Jul-17-25	Initiated	Goldman	Neutral
Jun-17-25	Initiated	Citigroup	Buy
Jun-10-25	Initiated	Stifel	Buy
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight
Dec-30-24	Initiated	H.C. Wainwright	Buy
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

View All

Newamsterdam Pharma Company Nv Stock (NAMS) Latest News

11:40 AM

Behavioral Patterns of NAMSW and Institutional Flows - Stock Traders Daily

11:40 AM

Mar 23, 2026

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session - The Manila Times

Mar 23, 2026

A cholesterol pill's kidney and safety data head to a major heart meeting - Stock Titan

Mar 23, 2026

Mar 22, 2026

JPMorgan Chase & Co. Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat

Mar 22, 2026

Mar 21, 2026

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 21, 2026

Mar 20, 2026

Earnings Update: How does NewAmsterdam Pharma Company NV Equity Warrant compare to its peersGap Up & Long Hold Capital Preservation Plans - baoquankhu1.vn

Mar 20, 2026

Does NewAmsterdam Pharma Company NV have declining or rising EPSEarnings Beat & AI Forecasted Stock Moves - baoquankhu1.vn

Mar 20, 2026

NAMS SEC FilingsNewAmsterdam Pharma Company N.V 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 20, 2026

(NAMS) Risk Channels and Responsive Allocation - Stock Traders Daily

Mar 20, 2026

Mar 19, 2026

Why is NewAmsterdam Pharma Company NV stock going downIPO Watch & Daily Oversold Bounce Ideas - baoquankhu1.vn

Mar 19, 2026

Mar 18, 2026

Truist initiates NewAmsterdam Pharma stock coverage with buy rating By Investing.com - Investing.com South Africa

Mar 18, 2026

Truist initiates NewAmsterdam Pharma stock coverage with buy rating - Investing.com

Mar 18, 2026

Published on: 2026-03-19 02:35:41 - baoquankhu1.vn

Mar 18, 2026

Mar 16, 2026